Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2025)
Aardvark Therapeutics (AARD) posted Net Equity Issued and Repurchased of $195000.0 for Q4 2025, up 100.23% sequentially from -$85.0 million in Q4 2024, and up 100.23% YoY from $97388.3 in Q4 2024.
Aardvark Therapeutics (AARD) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Aardvark Therapeutics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $195000.0 in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 100.23% year-over-year to $195000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$84.8 million (changed N/A YoY) and the FY2025 annual result came in at $195000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased rose to $195000.0 in Q4 2025 per AARD's latest filing, from -$85.0 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $195000.0 in Q4 2025 and troughed at -$85.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -85.00 Mn |
| Dec 31, 2024 | -85.00 Mn |